Who Supplies Darunavir to India from MALAYSIA

To import finished pharmaceutical formulations containing Darunavir into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application requires submission of Form 40 or 41, along with a No Objection Certificate (NOC) from the manufacturer. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data compliant with ICH Zone IV guidelines. The timeline for import drug registration varies but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory review. For Darunavir formulations under HS Code 30049099, specific requirements include detailed product dossiers, evidence of bioequivalence, and compliance with Indian Pharmacopoeia standards.

Imported Darunavir formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data must demonstrate a shelf life of at least 24 months under ICH Zone IV conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products. Failure to meet these requirements can result in rejection of the shipment and potential penalties.

Between April 2024 and April 2026, the CDSCO introduced stricter regulations for importing pharmaceutical products, including mandatory import registration and licensing for all imported drugs. The Production Linked Incentive (PLI) scheme, implemented in 2024, aims to boost domestic manufacturing and may impact the volume of finished formulation imports. Bilateral agreements between India and Malaysia have facilitated smoother trade processes, but compliance with updated regulatory standards remains essential.

India imports finished Darunavir formulations primarily due to the unavailability of certain patented or branded formulations domestically. Specific dosage forms, such as fixed-dose combinations, are often sourced from international markets. Domestic capacity for Darunavir formulations is limited, leading to a dependency on imports to meet patient needs. The market size for Darunavir formulations in India is substantial, with a growing demand driven by the prevalence of HIV/AIDS.

The Basic Customs Duty (BCD) for Darunavir formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Integrated Goods and Services Tax (IGST) is applicable at 12%, calculated on the sum of the CIF (Cost, Insurance, and Freight) value plus the total duty. Anti-dumping duties and exemptions are not currently applicable to Darunavir formulations. The total landed duty percentage is approximately 32.4%.

India sources Darunavir formulations from Malaysia due to competitive pricing, favorable trade relations, and the availability of specific dosage forms not manufactured domestically. Malaysia's adherence to international quality standards and GMP certifications enhances its appeal as a supplier. Other suppliers include China, Germany, and the United States; however, Malaysia's proximity and established trade agreements with India provide a competitive advantage. Malaysia's share in India's Darunavir import market is approximately 5%.

India imports Darunavir formulations from Malaysia due to the availability of specific dosage forms not produced domestically, such as fixed-dose combinations. Malaysia's competitive pricing and adherence to international quality standards make it an attractive sourcing option. The strategic location and established trade relations further facilitate efficient supply chain operations.

Compared to China, Germany, and the United States, Malaysia offers competitive pricing and shorter lead times due to its proximity. The quality of Malaysian pharmaceutical products is comparable to international standards, and the mutual recognition of GMP certifications simplifies regulatory approvals. Malaysia's unique advantage lies in its ability to supply specific Darunavir formulations that other countries may not offer.

Potential risks include currency fluctuations affecting cost structures, regulatory changes in Malaysia impacting production or export capabilities, and shipping disruptions due to unforeseen events. While Malaysia has a stable political environment, any changes in trade policies or bilateral relations could influence supply chain dynamics.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate risks associated with single-source dependency.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to secure transactions.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure compliance with quality and regulatory standards.
5. 5Regulatory Monitoring: Stay updated on changes in import regulations and tariffs to adapt procurement strategies accordingly.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Submit Form 40 or 41 to CDSCO for product registration.
3. 3Drug Import License: Apply for an import license under the Drugs and Cosmetics Act.
4. 4No Objection Certificate (NOC): Secure an NOC from the foreign manufacturer.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049099 to confirm classification and applicable duties.

1. 1Certificate of Analysis (CoA): Confirming product quality and compliance with specifications.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating GMP compliance and market authorization.